Pricing Strategies

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.

Industry says it is ready to work with the government on the recommendations from a major review of Australia’s health technology assessment system that covers areas such as discount rate reductions and setting up a separate budgetary allocation to temporarily subsidize access to certain drugs.

The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.

Cost watchdog NICE has blocked Leqembi’s use, but a pricing deal could unlock access to the beta-amyloid targeting drug

While the drug regulator has approved Eisai/Biogen’s early Alzheimer’s disease treatment, the health technology assessment institute is worried that its benefits are too small to justify its costs – a concern that Eisai has pledged to address.

Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding.

But the amount of savings realized when the Medicare negotiated prices go into effect in 2026 remains the subject of debate.

CBO estimated Medicare would get 50% net price reductions under the IRA, but CMS actually garnered 22%. The CBO analysis could not account for some of the particulars of the negotiations, but some health policy experts stressed any net gain over private Part D plan negotiation is a win.

Some manufacturers may have the dubious distinction of being targeted in the first and second rounds of the negotiation program, but at least will be familiar with the process the next time.

Net per drug savings achieved by the negotiation process is unclear because many of the products already have significant rebates. The announcement also leaves much of the agency’s negotiation process in the dark.

The latest figures on uptake for rivals to Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator, AbbVie’s Humira, after an initially slow start in 2023.

July’s UK generic pricing figures from WaveData show captopril tablets rocketing up in price, while aripiprazole prices continue to plummet.

Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.

The cost effectiveness watchdog claims AstraZeneca and Daiichi-Sankyo have not offered a fair price for use in the larger HER2-low setting.

Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.

Boehringer Ingelheim is partnering with GoodRx in the US to offer a version of its Humira biosimilar at a 92% discount to the brand’s list price. Generics Bulletin spoke with Chris Marsh, Boehringer’s senior vice president of value and access, about the initiative.

A number of diabetes drugs are also expected to be targeted in the next cycle of the price negotiation program, led by Novo Nordisk’s Ozempic.

The latest UK generic pricing information from WaveData shows multiple products doubling or even trebling their average prices in June.

Akebia said it had set the price for Vafseo at about $15,500 per year, meant to reflect its potential value in dialysis as well as eventually in non-dialysis patients.